CERo Therapeutics Holdings (CERo Therapeutics Holdings) EBITDA Margin % : 0.00% (As of Dec. 2022)

View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. CERo Therapeutics Holdings's EBITDA for the six months ended in Dec. 2022 was $-10.90 Mil. CERo Therapeutics Holdings's Revenue for the six months ended in Dec. 2022 was $0.00 Mil. Therefore, CERo Therapeutics Holdings's EBITDA margin for the quarter that ended in Dec. 2022 was 0.00%.

CERo Therapeutics Holdings EBITDA Margin % Historical Data

The historical data trend for CERo Therapeutics Holdings's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings EBITDA Margin % Chart

CERo Therapeutics Holdings Annual Data

Trend

Dec21

Dec22

EBITDA Margin %

CERo Therapeutics Holdings Semi-Annual Data
	Dec21	Dec22
EBITDA Margin %	-	-

Competitive Comparison of CERo Therapeutics Holdings's EBITDA Margin %

For the Biotechnology subindustry, CERo Therapeutics Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CERo Therapeutics Holdings's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CERo Therapeutics Holdings's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where CERo Therapeutics Holdings's EBITDA Margin % falls into.

CERo Therapeutics Holdings EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

CERo Therapeutics Holdings's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-10.898	/	0
	=	%

CERo Therapeutics Holdings's EBITDA Margin % for the quarter that ended in Dec. 2022 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2022 )	/	Revenue (Q: Dec. 2022 )
	=	-10.898	/	0
	=	%

CERo Therapeutics Holdings (NAS:CERO) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

CERo Therapeutics Holdings EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080

Website

https://www.cero.bio

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines

From GuruFocus

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

By Business Wire • 03-07-2024